LEXICON PHARMACEUTICALS, INC. (LXRX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 28,866 | 1,262 | 1,750 | 1,647 |
| Selling, general and administrative, including stock-based compensation of 1,575, 3,180, 3,044 and 5,888 respectively | 9,350 | 11,608 | 39,592 | 39,192 |
| Research and development | 15,747 | 15,303 | 25,780 | 17,643 |
| Cost of sales | 33 | 30 | 71 | 166 |
| Total operating expenses | 25,130 | 26,941 | 65,443 | 57,001 |
| Income (loss) from operations | 3,736 | -25,679 | -63,693 | -55,354 |
| Interest and other expense | 2,318 | 1,835 | 4,562 | 2,211 |
| Interest income and other | 1,834 | 2,219 | 3,444 | 4,136 |
| Net loss | 3,252 | -25,295 | -64,811 | -53,429 |
| Unrealized loss on investments | -39 | -94 | 542 | -143 |
| Comprehensive income (loss) | 3,213 | -25,389 | -64,269 | -53,572 |
| Net loss per common share, basic (usd per share) | 0.01 | -0.07 | -0.18 | -0.17 |
| Net loss per common share, diluted (usd per share) | 0.01 | -0.07 | -0.18 | -0.17 |
| Weighted average common shares outstanding, basic (in shares) | 363,294,000 | 362,073,000 | 361,492,000 | 310,836,000 |
| Weighted average common shares outstanding, diluted (in shares) | 363,570,000 | 362,073,000 | 361,492,000 | 310,836,000 |